Acute respiratory failure (ARF) is the leading cause of intensive care unit admission in patients with hematologic malignancies and is associated with a high mortality. The main causes of ARF are bacterial and opportunistic pulmonary infections and noninfectious lung disorders. Management consists of a systematic clinical evaluation aimed at identifying the most likely cause, which in turn determines the best first-line empirical treatments. The need for mechanical ventilation is a major determinant of prognosis. Beneficial outcomes have been demonstrated with early use of noninvasive ventilation (NIV) in selected patients with hematologic malignancies. However, most of these studies did not control the time between onset of ARF to NIV implementation nor accounted for the etiology of ARF or the presence of associated organ dysfunction at the time of NIV initiation. Moreover, the benefits demonstrated with NIV in these patients were derived from studies with high mortality rates of intubated patients. Additional studies are therefore warranted to determine the appropriate patients with hematologic malignancy and ARF who may benefit from prophylactic or curative NIV.
Introduction
Hematologic malignancies (leukemias, lymphomas, lymphoproliferative disorders, and plasma cell disorders) account for 20% of cancer diagnoses, with approximately 900 000 patients diagnosed annually worldwide. 1 Over the past 20 years, substantial diagnostic and therapeutic advances have increased the overall and disease-free survival of these patients. [2] [3] [4] However, these patients remain at risk of life-threatening infectious and noninfectious complications from either the toxicity of intensive cancer treatments including ionizing radiation, cytotoxic and targeted therapies, the more widespread use of allogeneic hematopoietic stem cell transplantation (HSCT), or from decompensation of comorbid conditions. As a result, the number of patients with hematological malignancies including those undergoing HSCT who are admitted to the intensive care unit (ICU) is increasing.
Acute respiratory failure (ARF) is the most common cause of ICU admission and the leading nonrelapse cause of mortality in this patient population. 5, 6 The condition occurs in 10% to 20% of patients with acute leukemia or lymphoma and in nearly 50% of patients with neutropenia or those undergoing HSCT. 7, 8 The need for invasive mechanical ventilation (IMV) is a major determinant of prognosis in these patients with ICU mortality exceeding 75% for those who develop the acute respiratory distress syndrome (ARDS). [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] In a previous article in this journal, Mokart and Saillard reviewed the diagnostic approach of ARF in patients with cancer. 19 The objective of this article is to review the contemporary management of the major causes of ARF in patients with hematological malignancies. For this review article, we conducted a focused PubMed search of the English medical literature over the past 15 years (January 2000-March 2015) of all the articles related to management of ARF in patients with hematologic malignancies. The key words used were ''cancer,'' ''tumor,'' ''malignancy,'' ''hematology patients,'' ''acute respiratory failure,'' ''intensive care,'' ''management,'' ''noninvasive ventilation,'' ''mechanical ventilation,'' ''invasive,'' ''prognosis,'' and ''outcomes.'' Relevant articles were read in full, and their reference lists were searched for relevant articles.
Management Principles General Measures
The management of ARF consists of a systematic clinical evaluation aimed at identifying the most likely cause (Figure 1 ), which in turn determines the best first-line empirical treatments. 6, 11 General supportive measures include supplemental oxygen to correct hypoxemia, diuretics to decrease pulmonary congestion, initiation of empiric antimicrobial therapy in patients with suspected pulmonary infection or sepsis, and use of noninvasive or invasive ventilatory support.
Pulmonary infections remain the most common cause of respiratory failure in hematological malignancies and in those receiving chemotherapy. Factors that are responsible for increased risk of pulmonary infection include defects in humoral or cell-mediated immunity, neutropenia, use of corticosteroids, exposure to multiple antibiotics, and prolonged course of hospitalization. Schnell et al studied the performance of the DIRECT criteria for identifying the most likely causes of ARF in patients with cancer (n ¼ 424) admitted to the ICU. 20 The mnemonic DIRECT represents Delay since malignancy onset or HSCT, since symptom onset and since implementation of antibiotics/prophylaxis, Pattern of immune deficiency, Radiographic appearance, Experience and knowledge of the literature, Clinical picture (including ongoing chemoprophylaxis and effective antibiotic therapy) and Findings by high-resolution computed tomography. The main causes of ARF were bacterial infections (n ¼ 201, 47%), opportunistic pulmonary infections (n ¼ 131, 31%), and noninfectious lung disorders (n ¼ 92, 22%). Bacterial infections were microbiologically documented in 40% and clinically documented in 60%. Bacterial pneumonias (either microbiologically or clinically documented) more often had delays of <3 days since symptom onset and were associated with neutropenia (absolute neutrophil count [ANC] < 500 cells/mm 3 ), solid tumors, and multiple myeloma. The most common opportunistic pulmonary infections were invasive pulmonary aspergillosis (31%), respiratory viral infections (28%), and Pneumocystis jiroveci pneumonia (27.5%). Noninfectious lung disorders included pulmonary edema (49%), lung cancer or metastasis (49%), and pulmonary drug toxicity due to bleomycin and rituximab (2%). 20 
Management of Infectious Causes of ARF Bacterial Pneumonias
Characteristic features of bacterial pneumonia in patients with hematologic malignancies include unilateral radiological changes, unilateral crackles, and presence of shock on ICU admission. 20 Atypical presentations may also occur. Fever is commonly seen but cough, sputum production, and classic lobar consolidation are often missing in patients with cancer. 19 Initial imaging is either normal or shows diffuse interstitial infiltrates. Pulmonary infiltrates are seen in 15% to 20% in febrile neutropenia (ANC < 500 cells/mm 3 ) and are associated with increased mortality. In patients with impaired humoral (B-cell) immunity such as acute or chronic lymphocytic leukemia and multiple myeloma, bacterial infections with Streptococcus pneumoniae and Hemophilus influenzae are more frequent. In patients with chemotherapy-induced neutropenia, bacterial infections are primarily caused by Staphylococcus aureus, Streptococcus pneumoniae, and gram-negative enteric bacilli (Pseudomonas aeruginosa and Klebsiella pneumoniae). In patients with impaired cellular (T-cell) immunity, infections can occur from Legionella pneumophila, Nocardia asteroides, Rhodococcus equi, and Mycobacterium tuberculosis. 19 Empiric broad-spectrum antibiotic therapy should be started promptly, especially in patients with febrile neutropenia and tailored down according to the culture results obtained using invasive or noninvasive diagnostic techniques. Choice of initial antibiotic for community-acquired, hospital-acquired, ventilatorassociated, and aspiration bacterial pneumonias (Table 1) should consider the type, 21-23 frequency of occurrence, and antibiotic susceptibility of the bacterial pathogens isolated (antibiogram) in the hospital. In patients with neutropenic septic shock, survival has improved over time. 24, 25 The recommended duration of antimicrobial therapy for patients with hospital-acquired or ventilatorassociated pneumonia is 7 to 8 days; a longer course (up to 14 days) is required for multidrug resistant pathogens. 26 For critically ill hospitalized patients with cancer having Legionella pneumonia, a 21-day course of levofloxacin is recommended.
Viral Infections
Community-acquired respiratory viruses such as influenza, respiratory syncytial virus (RSV), and parainfluenza may cause serious pneumonias in patients with hematologic malignancies. 27 Infections with these viruses are commonly associated with bacterial or fungal copathogens. Currently, polymerase chain reaction (PCR)-based molecular diagnostics have replaced traditional methods such as viral culture, serologic testing, and fluorescent antibody assays and enzyme immunoassays for diagnosing viral infections, especially among allogenic HSCT recipients. 19, 28 Specific management depends on the type of virus infection ( Table 2) . Mortality rates following influenza pneumonia can range from 15% to 28%. The 2 main classes of anti-influenza drugs are neuraminidase inhibitors (eg, oseltamivir and zanamivir) and M2 inhibitors (eg, amantadine and rimantadine). Prompt initiation of therapy, preferably within 24 to 48 hours of onset of symptoms, is essential. A long-acting neuraminidase inhibitor, laninamivir, had efficacy comparable to that of oseltamivir. 31 In one large series, RSV pneumonia-attributable mortality was 18% and was associated with severe immunodeficiency, lower respiratory tract infection, and the pre-engraftment period. 32 Aerosolized ribavirin is the current treatment of choice for RSV pneumonia in HSCT recipients. 33 Intravenous immunoglobulin (IVIG) has been used in severe cases as adjunctive therapy. Therapy with palivizumab, a monoclonal antibody, has shown benefit in children. 34 Human parainfluenza virus type (HPIV) 3 is the most commonly detected type in leukemia and HSCT patients (80%-90%) followed by HPIV1 and 2. Reported risk factors are higher corticosteroid exposure, neutropenia, lymphopenia, infection early after allogeneic HSCT, a higher Acute Physiology and Chronic Health Evaluation II (APACHE II) score, and coinfections. 35 Treatment options are limited by the lack of effective agents and randomized controlled trials (RCTs), and some centers consider treating HPIV with ribavirin and/or IVIG. 36 Human metapneumovirus (HMPV) is genetically very similar to RSV and is reported to infect about 5% to 9% of HSCT recipients with mortality rate higher with the development of pneumonia (33%-40%). A recent study examined the efficacy of ribavirin combined with IVIG in HSCT recipients with HMPV pneumonia and found no difference in mortality rates. 37 The risk for cytomegalovirus (CMV) pneumonia is high with the use of chemotherapeutic agents such as cytarabine and fludarabine, treatment with T-cell suppressor agents such as corticosteroids and methotrexate, and T-cell depleting drugs such as rituximab and alemtuzumab. The treatment of choice is ganciclovir or foscarnet. 38 CMV-specific immunoglobulin (CMV-IVIG) has been used for the treatment of CMV pneumonitis in allogeneic HSCT recipients and may improve outcomes if used in combination with antiviral therapy. 39 Adenovirus infections in HSCT recipients are also increasingly recognized as significant causes of morbidity and mortality. Treatment of severe adenovirus disease with cidofovir has been associated with clinical improvement in HSCT patients. 40 
Fungal Infections
Pneumocystis jiroveci pneumonia (PCP) is more common in hematological cancers (leukemias and lymphomas) than with solid tumors. 41 The CMV coinfection is common with PCP. The PCR on induced sputum is usually the initial procedure for the diagnosis of PCP. If PCP is not identified with this modality, then bronchoscopy with bronchoalveolar lavage (BAL) should be performed. Although the b-D-glucan assay is not specific for PCP, it can be useful for early detection of PCP (eg, while awaiting the results of the induced sputum or BAL specimen). Trimethoprim/sulfamethoxazole (TMP/SMX) is the drug of choice; however, its efficacy may be suboptimal in patients with cancer. 42 but no studies have been done to prove efficacy. In patients with PCP who are intolerant of or refractory to high-dose TMP/SMX, a combination of clindamycin plus primaquine is the preferred alternative. Adjunctive use of glucocorticosteroids is not generally recommended and should only be considered in individual patients. Patients who have been successfully treated for PCP pneumonia should receive secondary oral prophylaxis with intermittent TMP/SMX or monthly pentamidine to prevent recurrence. 29 Aspergillosis is seen in 30% of severe cases with neutropenia and mainly affects the lungs and sinuses, with mortality rates as high as 60%. 43 Two patterns of invasive pulmonary aspergillosis have been described: angioinvasive pulmonary aspergillosis characterized by vascular invasion by Aspergillus and a nodule with a halo sign on computed tomography (CT) scan, and airway-invasive aspergillosis characterized by the destruction of the bronchiolar wall and centrilobular micronodules and tree-in-bud opacities on CT scan. 44 The gold standard for diagnosis is detection of hyphae by histopathologic or cytopathologic examination of lung tissue. Voriconazole is now considered the drug of choice for invasive aspergillosis, as it has been shown to be more efficacious with fewer side effects than amphotericin B. [45] [46] [47] Posaconazole and caspofungin have been used in refractory cases with partial response. Although many experts still recommend voriconazole monotherapy, a recent study showed that combination therapy with anidulafungin led to higher survival in patients with invasive aspergillosis. 48 The duration of antifungal therapy depends upon the location of the infection, the patient's underlying disease and need for further immunosuppression, and the response to initial week of therapy (patients with decreasing levels of b-D-glucan have better survival rates). For most immunosuppressed patients, antifungal therapy will continue for months or even years in some cases. If an invasive mold infection is suspected and the likelihood of mucormycosis is increased due to recent receipt of voriconazole, lipid formulation of amphotericin B (AmBisome or Abelcet) rather than voriconazole is recommended to provide antifungal activity against both aspergillosis and mucormycosis. Whenever possible, immunosuppression should be decreased as an adjunct to antifungal therapy. Fusarium species frequently involve the lungs and skin and are associated with an overall mortality of 50% to 80% in HSCT recipients especially because of their high rate of drug resistance. Diagnosis is difficult to make due to the poor sensitivity of respiratory cultures. Combination therapy of amphotericin B and voriconazole and radical surgical debridement are the recommended treatments. Other fungal infections that are frequently seen include invasive candidiasis and mucormycosis. 49 Treatment and duration of antimicrobial therapy for fungal pneumonias are shown in Table 2 .
Management of Noninfectious Causes of ARF
Noninfectious etiologies of ARF in patients with hematologic malignancies include cardiogenic pulmonary edema (CPE), pulmonary hemorrhage, aspiration pneumonitis, radiationinduced pneumonitis, venous thromboembolism, transfusionrelated acute lung injury (TRALI), retinoic acid syndrome, leukemic pulmonary leukostasis, leukemic pulmonary infiltrates, and pulmonary lysis syndrome. 19, 20, 50, 51 Specific management depends on the noninfectious disorder causing the ARF (Table 3) .
Cardiogenic pulmonary edema is the most common noninfectious complication that results in ARF in these patients. It is a frequent early complication that is attributed to large amounts of intravenous fluids needed to administer antibiotics, blood products, cytotoxic drugs (eg, anthracycline), and parenteral nutrition. Patients with CPE tend to have rapid improvement of symptoms with diuretics, which is also useful for diagnosis. Cardiac dysfunction and pulmonary edema may be exacerbated by the development of acute renal failure due to the cancer, drug-related tubular toxicity, or malignant cell lysis. Management includes adequate diuresis, judicious use of fluids and blood products, and noninvasive ventilation if needed.
Pulmonary hemorrhage is relatively common in patients with acute leukemia and HSCT and is usually associated with thrombocytopenia, coagulopathy, and infectious disorders. Management of TRALI is primarily supportive with supplemental oxygen and judicious use of diuretics, although, in severe cases, intubation and mechanical ventilation may be required. The majority of patients recover within 72 to 96 hours.
Retinoic acid syndrome (differentiation syndrome) is caused by all-trans retinoic acid (ATRA) that is used to treat acute promyelocytic leukemia. 52 It is associated with fever, respiratory distress, and diffuse ground-glass opacities on chest imaging. Early recognition and aggressive management with dexamethasone therapy (10 mg intravenously every 12 hours for > 3 days) has been effective in most patients. 53 Early discontinuation of ATRA can be considered in severe patients who are not responding to corticosteroids. All-trans retinoic acid can be restarted at a lower dose in most cases once the syndrome has resolved.
Distinguishing among leukostasis, leukemic infiltration, and acute lysis pneumopathy may be difficult, particularly as these conditions may occur concomitantly. Pulmonary leukostasis are associated mainly with acute myeloid leukemia and the blast phase of chronic myeloid leukemia, when the leukocyte count is greater than 100 000/mm 3 or increases rapidly whereas leukemic infiltration of the lungs has been reported in acute leukemia with or without hyperleukocytosis. 20 Acute lysis pneumopathy develops after chemotherapy initiation likely due to lysis of leukemic cells with release of cell contents leading to diffuse alveolar damage. Hemophagocytic lymphohistiocytosis is a rare but highly fatal disease if untreated. Early diagnosis and treatment are mandatory to increase the chances of survival. 54 It occurs secondary to life-threatening hyperinflammation caused by excessive levels of cytokines, which is often difficult to differentiate from severe sepsis. In patients without underlying systemic diseases, etoposide combined with corticosteroid therapy is the recommended treatment.
Among HSCT recipients, noninfectious pulmonary complications can occur during the pre-engraftment period (hyperacute graft versus host disease [GVHD], peri-engraftment respiratory distress syndrome [PERDS], and diffuse alveolar hemorrhage [DAH]), early postengraftment (idiopathic pneumonia syndrome and sinusoidal obstruction syndrome), and late postengraftment (pulmonary alveolar proteinosis, pulmonary veno-occlusive disease [PVOD], cryptogenic organizing pneumonia [COP], posttransplant lymphoproliferative disease, and bronchiolitis obliterans syndrome [BOS]). 19, 20, 50, 51 Management strategies for these disorders are shown in Table 4 . Corticosteroids have been shown to benefit HSCT patients with ARF associated with hyperacute GVHD, PERDS, and DAH during the pre-engraftment period as well as IPS, COP, and BOS during the postengraftment period. Defibrotide, a deoxyribonucleic derivative with fibrinolytic activity, has been used successfully to treat pulmonary veno-occlusive disease.
Ventilatory Management of ARF
The clinician must carefully weigh the benefits and risks of the initial mode of ventilatory support (noninvasive or invasive) in patients with hematologic malignancies (Figure 2 ). Noninvasive positive pressure ventilation (NIPPV) consists of the delivery of mechanically assisted positive airway pressure breaths using a nasal or facial mask. The use of NIPPV is indicated for patients with hypercarbic chronic obstructive pulmonary disease (COPD) exacerbation or cardiac pulmonary edema. Major contraindications to NIPPV include hemodynamic instability or shock, respiratory or cardiac arrest, cardiac arrhythmias, any degree of nonrespiratory organ failure, excessive secretions, altered sensorium or encephalopathy unless due to hypercarbia, severe upper gastrointestinal bleeding, recent facial or head and neck surgery, facial deformity, and upper airway obstruction secondary to tumor involvement. 9, 55 Noninvasive positive pressure ventilation has 2 major modes of ventilatory support, namely, continuous positive airway pressure (CPAP) 55 and bilevel positive airway pressure (BiPAP). Inspiratory and expiratory pressures are individualized based on patient tolerance and clinical status. Treatment is generally started with relatively low pressures and gradually titrated up with close bedside monitoring of patient comfort, ventilator synchrony, tidal volumes, and vital signs.
Common complications of NIPPV include pressure ulcers over the nasal bridge, mucosal pain, sinus congestion, and gastric insufflation (particularly with inspiratory pressures > 20 mm Hg). Invasive positive pressure ventilation should be avoided in patients with a history of diaphragmatic hernia or Morgagni hernia as it can exacerbate the respiratory failure. 56 The need for arterial blood gas (ABG) analysis will be governed by the patient's clinical progress but should be measured in most patients after 1 to 2 hours of NIPPV and after 4 to 6 hours if the earlier ABG sample showed little improvement. If there has been no improvement in PaCO 2 and pH after this 4-to 6-hour period, despite optimal settings, NIPPV should be discontinued and IMV considered. Patients with higher severity of illness as evaluated by Simplified Acute Physiology Score II (SAPS II) of >35 and PaO 2 /FiO 2 after 1 hour on NIPPV had a higher probability of requiring IMV after NIPPV. 57 A few studies have demonstrated beneficial outcomes with early use of NIPPV in patients with hematological malignancies (Table 5 ). [58] [59] [60] [61] Adda et al retrospectively analyzed 99 patients with hematologic malignancies who were admitted to the ICU over a 10-year period (1995-2005) and received NIPPV. 59 Of these, 53 (54%) patients failed NIPPV and required IMV. Hospital mortality in these patients was high when compared to those who succeeded with NIPPV (79% vs 41%, respectively). Multivariate analysis revealed that a high respiratory rate during NIPPV (32 breaths/min [30] [31] [32] [33] [34] [35] [36] vs 28 [27] [28] [29] [30] ), longer delay from ICU admission to NIPPV, need for vasopressors or renal replacement therapy (RRT), and meeting oxygenation criteria for ARDS (PaO 2 /FiO 2 ratio of 175 [101-236] vs 248 [134-337]) were independent predictors of NIV failure. Patients who failed NIPPV had a significantly longer ICU stay (13 days [8-23] vs 5 [2] [3] [4] [5] [6] [7] [8] ) and a significantly higher rate of ICU-acquired infections (32% vs 7%). The ICU mortality in patients who failed NIPPV was greater than the early intubation group (61% vs 50%, P < .01). The authors concluded that intubation should be considered early in patients who remain tachypneic during NIPPV and in those with severe hypoxemia.
Depuydt et al similarly analyzed 137 hematological patients admitted to the ICU with ARF (defined as PaO 2 / FiO 2 < 200) within the first 24 hours. 60 Of these, 24 (17.5%) received NIPPV, 67 (48.9%) required IMV, and 46 (33.6%) received supplemental oxygen only. The ICU mortality rates in these 3 subgroups were 71%, 63%, and 32%, respectively (P ¼ .001), and in-hospital mortality rates were 75%, 80%, and 47%, respectively (P ¼ .001). The authors found that increasing cancer-specific severity-of-illness score on ICU admission and more organ failure after 24 hours of admission, but not the type of initial respiratory support, were associated with ICU or in-hospital mortality.
Gristina et al retrospectively analyzed 1302 patients with hematological malignancies who were admitted to several Italian ICUs with ARF between 2002 and 2006. 61 Of these, 21% initially received NIPPV, and 46% of these patients subsequently required IMV. Outcomes were better among patients who had successful use of NIPPV (58% survival) compared to both those who required IMV from the onset of ARF (31% survival) and those who required IMV after NIPPV failure (23% survival), especially in patients with ARDS. Delayed IMV was also associated with slightly higher mortality than immediate IMV but was not statistically significant (65% vs 58%, P ¼ .12). After propensity-score adjustment, NIPPV was associated with significantly lower mortality than IMV. It is important to note that most of the studies demonstrating benefit of NIPPV did not control the time between the onset of ARF to NIPPV implementation nor accounted for the etiology of ARF or the presence of associated organ dysfunction at the time of NIPPV initiation. Moreover, the benefits demonstrated from the use of NIPPV in patients with hematological cancer were derived from studies with high mortality rates of intubated patients. 67 When to Switch From Noninvasive to IMV There are several situations when NIPPV should be switched to IMV, and these situations should be recognized promptly to avoid adverse outcomes. These include the following: (a) increasing respiratory deterioration (as evidenced by a >20% decrease in PaO 2 /FiO 2 or a 20% increase in PaCO 2 , or signs of respiratory muscle fatigue such as paradoxical abdominal movement), despite maximal tolerable NIV settings; (b) increasing hemodynamic instability (defined as the use of norepinephrine exceeding > 10 mg/min); (c) neurological deterioration (defined as development of agitation or somnolence; Glasgow Coma Scale <13); and (d) intolerance/dyssynchrony of NIPPV. 57, 68 It is not uncommon for patients on NIPPV to require IMV especially when the underlying condition leading to ARF has not resolved in a timely manner or has clinically worsened.
Prophylactic Use of Noninvasive Ventilation
A few studies have examined the prophylactic use of NIPPV in patients having hematologic cancer with hypoxemic respiratory insufficiency. 58, [69] [70] [71] In a single center RCT, Hilbert et al reported significant benefit from NIPPV in hypoxemic immunocompromised patients (including 30 hematology patients). 58 However, Wermke et al recently demonstrated that NIPPV performed in the hematology wards was ineffective in patients with hypoxemia undergoing allogenic HSCT. 69 The authors attributed this finding to inadequate training of clinicians and timely management of these patients with titration of NIPPV settings. In contrast, in a similar study where nursing and medical teams had greater NIV experience and with strict intensivist supervision of NIPPV on the wards, Squadrone et al showed that CPAP use resulted in a significant reduction in ICU admission and need for IMV and was associated with higher survival. 70 Overall, prophylactic NIV is a reasonable and safe strategy in a closely monitored setting. However, additional studies are needed to select the ideal candidate who will benefit from prophylactic NIV.
Settings of Prophylactic NIV
At the start of NIPPV, the clinician should set the positive end-expiratory pressure (PEEP) to 7 cm of H 2 O and pressure support (PS) to 15 cm of H 2 O. Later, these values can be adjusted according to patient tolerance and ABG analysis. In one study of HSCT patients with ARF, NIPPV was administered intermittently for at least 30 minutes every 3 hours with response assessed twice daily by monitoring the oxygenation index (OI), arterial oxygen saturation, and respiratory rate. 69 The OI was shown to be an independent risk factor for overall survival in these patients.
Weaning/Liberation From IMV to NIV
Some investigators have examined the use of NIPPV to facilitate discontinuation of IMV. Vaschetto et al evaluated the benefit of early extubation followed by NIPPV versus invasive PS (control group) to facilitate weaning and extubation in 20 selected patients with resolving hypoxemic ARF. 72 The number of IMV-free days at day 28 was 20 + 8 days in the NIPPV group versus 10 + 9 days in the control group (P ¼ .014). The rate of extubation failure, ICU and hospital mortality, number of tracheotomies, septic complications, days and rates of continuous sedation, and ICU length of stay were not significantly different between the 2 groups. The study, however, was limited by the small sample size, heterogeneous patient population which included trauma patients, and the different weaning strategies. A systematic review of 16 trials involving 994 participants, predominantly with chronic pulmonary obstructive disease, showed that a weaning strategy that includes NPPV reduced the rates of mortality and ventilator-associated pneumonia without increasing the risk of weaning failure or reintubation. 73 
Noninvasive Positive Pressure Ventilation in Patients With Do Not Intubate or Intractable Dyspnea
Noninvasive positive pressure ventilation can be an option in patients with do not intubate code status but still request for aggressive supportive interventions. This approach was endorsed by an international consensus conference on NIPPV 74 in selected patients with cancer who are likely to have reversible causes of ARF (e.g., acute CPE, pulmonary infection, or COPD exacerbation). Noninvasive positive pressure ventilation may also be an alternative measure to treat intractable dyspnea, as demonstrated by the use of nocturnal NIPPV showing relief of symptoms. 75 However, NIPPV should not be used to prolong life in patients with terminal respiratory failure.
Feasibility of High-Flow Nasal Cannula Oxygen Therapy
High-flow nasal cannula (HFNC) delivers heated humidified oxygen up to 100% at a maximum flow rate of 60 L/min of gas via nasal prongs which match patient flow demands better, reduce anatomic dead space, and provide some amount of positive pressure in the airway. 76 In a retrospective single center study of 45 patients with hematologic malignancies and ARF predominantly due to bacterial pneumonia and PCP pneumonia, Lee et al demonstrated that the use of HFNC was feasible, with a failure rate of 67%, similar to that of NIV failure rates reported in previous studies. 77 
General Principles for IMV
Patients who immediately or ultimately require IMV for severe respiratory failure or ARDS need to be managed using low tidal volumes (ideally 6 mL/kg of predicted body weight) and targeting inspiratory plateau pressures < 30 cm H 2 O, 78 judicious titration of PEEP, conservative fluid management, and close hemodynamic monitoring. Using dexmedetomidine or propofol-based sedation regimen rather than a benzodiazepine-based sedation regimen may reduce ICU length of stay and duration of mechanical ventilation. 79 In refractory cases, the use of prone positioning, 80 high-frequency oscillatory ventilation, recruitment maneuvers, vasodilator therapy, and extracorporeal oxygenation (ECMO) may be considered as well as the adjunctive use of neuromuscular blocking agents 81 and corticosteroids although the routine use of the latter remains controversial and requires further study. It is important to note that many of the clinical trials in ARDS excluded patients with hematologic malignancies or those undergoing HSCT.
Extracorporeal Membrane Oxygenation
In the recent years, there has been increasing use of ECMO as a therapeutic option for ARDS in patients who do not respond to conventional mechanical ventilation strategies. 82 Although ECMO has been shown to be associated with better outcomes in a few select studies, there is limited data available in patients with hematological malignancies. 83 
Outcomes and Prognosis
Studies in the late 1990s and early 2000s revealed ICU and inhospital mortality rates ranging from 30% to 50% and 50% to 70%, respectively. 5, 85 Similarly, the 3 to 5-year survival of these patients also remains low, especially when mechanical ventilation is needed. Several risk factors have been shown to affect mortality in patients with hematologic malignancies including those undergoing HSCT who develop ARF. These include race (African Americans and Hispanics have higher mortality rates), 5 poor performance status, 64 poor Charlson comorbidity index, allogeneic HSCT, higher SAPS II score, 13, 61 high level of C-reactive protein on ICU admission, 14 presence of acute lung injury/ARDS on ICU admission, presence of shock requiring vasopressors or need for RRT, 6 failure to identify the pathogen causing the pulmonary infiltrate, 6,58 malignant organ infiltration with leukemia or lymphoma, documented invasive aspergillosis, 43 ARF due to pulmonary toxicity from chemotherapy, and >96 hours of IMV. 16 One study showed better survival of critically ill hematology patients with ARF in ICUs with higher case volume. 6 Interestingly, the type of hematological malignancy was not an independent risk factor for ICU mortality. 7, 8 The improved outcomes in recent years 4, 24, 25, 86 can be explained by use of selection criteria such as good performance status, endotracheal intubation within the first 24 hours of ICU admission, 62 and availability of chemotherapy options. Good prognostic factors include requirement of minimal life support intervention and time of admission to ICU <24 hours, 64 as studies have shown poor prognosis if duration to ICU admission was >2 days with or without intubation. 63 Improvement in mortality in patients who are admitted to ICU with or without need of ventilatory support can be explained by progress in early use of NIV and lung protective ventilation strategies and major changes in antimicrobial therapy. A more recent study of patients with cancer admitted to the ICU requiring NIPPV or IMV similarly showed improved hospital survival among patients with good performance status and nonprogressive malignancy and without tumor involvement of the airway. 66 Among HSCT recipients who develop ARF, the overall inhospital mortality rate is around 50%. After adjusting for a multitude of patient-and hospital-level factors, any need for IMV in this subgroup of patients with ARF was associated with worse outcomes, with mortality as high as 90% to 97% if neutropenia is present. Several studies have established that ICU mortality is no longer linked to the characteristics of the underlying disease but depends instead on the severity and reversibility of the ARF event. 7 In particular, mortality is higher when investigations fail to identify the cause of ARF.
Other studies have showed that HSCT recipients who respond well to 4 hours of NIV have a good prognosis. Criteria for response include increase in PaO 2 /FiO 2 by 20%, a decrease in respiratory rate, and a low Crawford score. The combination of lung injury with hepatic and renal failure or mechanical ventilation has an extremely high mortality rate. Boyaci et al reported that baseline APACHE II score and requirement for vasopressors during the ICU stay were the most significant independent risk factors for mortality among HSCT recipients. 65 In a multicenter prospective study of 1011 patients with hematologic malignancy who were admitted to ICUs in France and Belgium, 25% of whom had undergone HSCT, patients Azoulay et al reported a hospital mortality rate of 39.3%. 64 This is certainly encouraging, particularly as most patients had at least 2 organ dysfunctions with 75% of them requiring mechanical ventilation, vasoactive drugs, or RRT. These patients had no health-related quality of life (HRQOL) alterations after 3 months compared to patients who were not admitted to the ICU and had 80% disease-control rate after 6 months.
Conclusion
Acute respiratory failure is the most common cause of ICU admission and the leading nonrelapse cause of mortality in patients with hematologic malignancies. The need for mechanical ventilation is a major determinant of prognosis in these patients with ICU mortality exceeding 75% for those who develop ARDS. The main causes of ARF are bacterial infections, opportunistic pulmonary infections, and noninfectious lung disorders. Empiric broad spectrum antibiotic therapy should be started promptly, especially in patients with febrile neutropenia and ARF. Although several reports have demonstrated beneficial outcomes with early use of NIPPV in appropriately selected patients with hematologic malignancies, additional studies are still needed to determine the ideal patients who will benefit from prophylactic or curative NIV.
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